GenMark Diagnostics Inc.

24.01+0.0200+0.08%Vol 1.19M1Y Perf 211.82%
Apr 16th, 2021 16:00 DELAYED
BID24.00 ASK24.03
Open24.03 Previous Close23.99
Pre-Market- After-Market23.99
 - -  -0.02 -0.08%
Target Price
22.01 
Analyst Rating
Moderate Buy 1.83
Potential %
-8.33 
Finscreener Ranking
★+     45.14
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★+     50.03
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★+     43.29
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap1.75B 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
98.60 
Earnings Date
3rd May 2021

Today's Price Range

23.9924.03

52W Range

7.0924.25

5 Year PE Ratio Range

-4.90-7.30

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
0.08%
1 Month
0.54%
3 Months
69.80%
6 Months
104.86%
1 Year
211.82%
3 Years
338.14%
5 Years
347.11%
10 Years
397.00%

TickerPriceChg.Chg.%
GNMK24.010.02000.08
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Financial StrengthValueIndustryS&P 500US Markets
3.40
3.90
0.47
0.93
-1.30
Leverage Ratio 2.30
ProfitabilityValueIndustryS&P 500US Markets
38.80
-11.60
-6.70
-71.20
-8.46
RevenueValueIndustryS&P 500US Markets
132.81M
1.80
39.64
30.34
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.01-0.05-400.00
Q03 2020-0.06-0.0516.67
Q02 2020-0.10-0.0730.00
Q01 2020-0.16-0.0475.00
Q04 2019-0.16-0.17-6.25
Q03 2019-0.19-0.20-5.26
Q02 2019-0.21-0.23-9.52
Q01 2019-0.21-0.210.00
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.05-600.00Negative
6/2021 QR-0.06-20.00Negative
12/2021 FY-0.12-100.00Negative
12/2022 FY0.14-64.10Negative
Next Report Date3rd May 2021
Estimated EPS Next Report-0.05
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume1.19M
Shares Outstanding73.09M
Trades Count5.78K
Dollar Volume22.19M
Avg. Volume2.69M
Avg. Weekly Volume2.97M
Avg. Monthly Volume3.42M
Avg. Quarterly Volume2.98M

GenMark Diagnostics Inc. (NASDAQ: GNMK) stock closed at 24.01 per share at the end of the most recent trading day (a 0.08% change compared to the prior day closing price) with a volume of 1.24M shares and market capitalization of 1.75B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 618 people. GenMark Diagnostics Inc. CEO is Scott Mendel.

The one-year performance of GenMark Diagnostics Inc. stock is 211.82%, while year-to-date (YTD) performance is 64.45%. GNMK stock has a five-year performance of 347.11%. Its 52-week range is between 7.09 and 24.25, which gives GNMK stock a 52-week price range ratio of 98.60%

GenMark Diagnostics Inc. currently has a PE ratio of -82.60, a price-to-book (PB) ratio of 18.71, a price-to-sale (PS) ratio of 13.29, a price to cashflow ratio of 263.70, a PEG ratio of 2.32, a ROA of -10.81%, a ROC of -16.38% and a ROE of -34.71%. The company’s profit margin is -8.46%, its EBITDA margin is -6.70%, and its revenue ttm is $132.81 Million , which makes it $1.80 revenue per share.

Of the last four earnings reports from GenMark Diagnostics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.05 for the next earnings report. GenMark Diagnostics Inc.’s next earnings report date is 03rd May 2021.

The consensus rating of Wall Street analysts for GenMark Diagnostics Inc. is Moderate Buy (1.83), with a target price of $22.01, which is -8.33% compared to the current price. The earnings rating for GenMark Diagnostics Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

GenMark Diagnostics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

GenMark Diagnostics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 13.62, ATR14 : 1.05, CCI20 : 17.01, Chaikin Money Flow : -0.09, MACD : 1.68, Money Flow Index : 65.71, ROC : -0.17, RSI : 59.58, STOCH (14,3) : 44.74, STOCH RSI : 0.91, UO : 45.63, Williams %R : -55.26), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of GenMark Diagnostics Inc. in the last 12-months were: Alan Baer Maderazo (Option Excercise at a value of $1 497 571), Alan Baer Maderazo (Sold 213 578 shares of value $3 142 605 ), Brian Andrew Mitchell (Sold 84 324 shares of value $1 172 692 ), Christine Shaw (Sold 5 292 shares of value $85 824 ), Daryl J. Faulkner (Option Excercise at a value of $173 400), Eric Stier (Option Excercise at a value of $0), Eric Stier (Sold 99 870 shares of value $1 312 631 ), John Frederick Ek (Option Excercise at a value of $0), John Frederick Ek (Sold 106 449 shares of value $1 533 918 ), Michael Gleeson (Option Excercise at a value of $368 736), Michael Gleeson (Sold 69 250 shares of value $1 047 749 ), Michael John Harkins (Option Excercise at a value of $0), Michael John Harkins (Sold 27 104 shares of value $409 486 ), Sarah Hollis Winkler (Option Excercise at a value of $0), Sarah Hollis Winkler (Sold 26 480 shares of value $408 038 ), Scott Alexander O'Brien (Option Excercise at a value of $0), Scott Alexander O'Brien (Sold 50 217 shares of value $743 162 ), Scott Mendel (Option Excercise at a value of $0), Scott Mendel (Sold 362 046 shares of value $5 231 896 ), Tyler Jensen (Option Excercise at a value of $376 665), Tyler Jensen (Sold 94 648 shares of value $1 535 789 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (50.00 %)
3 (50.00 %)
3 (50.00 %)
Moderate Buy
1 (16.67 %)
1 (16.67 %)
1 (16.67 %)
Hold
2 (33.33 %)
2 (33.33 %)
2 (33.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.83
Moderate Buy
1.83
Moderate Buy
1.83

GenMark Diagnostics Inc.

GenMark Diagnostics Inc is a provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment. The company currently operates in one reportable business segment, which encompasses the development, manufacturing, sales, and support of instruments and molecular tests based on its proprietary eSensor detection technology. Its operations and assets are in the United States of America.

CEO: Scott Mendel

Telephone: +1 760 448-4300

Address: 5964 La Place Court, Carlsbad 92008-8829, CA, US

Number of employees: 618

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

55%45%

Bearish Bullish

52%48%

News

Stocktwits